12:00 AM
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LY2605541: Additional Phase II data

Additional data from 108 Type I diabetics who completed treatment in an open-label, crossover, U.S. and Israeli Phase II trial showed that once-daily subcutaneous LY2605541 significantly reduced total daily insulin use by 20.7% compared to Lantus insulin glargine at week 8 (p=0.005). Compared to Lantus, LY2605541 also significantly reduced mealtime insulin use at breakfast by 13.7% (p=0.021), at lunch by 18.6%...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >